ATE273712T1 - Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer - Google Patents

Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer

Info

Publication number
ATE273712T1
ATE273712T1 AT97902278T AT97902278T ATE273712T1 AT E273712 T1 ATE273712 T1 AT E273712T1 AT 97902278 T AT97902278 T AT 97902278T AT 97902278 T AT97902278 T AT 97902278T AT E273712 T1 ATE273712 T1 AT E273712T1
Authority
AT
Austria
Prior art keywords
inactivation
ras
compounds therefor
ras subfamily
subfamily proteins
Prior art date
Application number
AT97902278T
Other languages
English (en)
Inventor
Eichel-Streiber Christoph Von
Patrice Boquet
Monica Thelestam
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Application granted granted Critical
Publication of ATE273712T1 publication Critical patent/ATE273712T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6829Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97902278T 1996-02-02 1997-01-31 Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer ATE273712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96101469 1996-02-02
PCT/EP1997/000426 WO1997027871A1 (en) 1996-02-02 1997-01-31 Method of inactivation of ras subfamily proteins and agents therefor

Publications (1)

Publication Number Publication Date
ATE273712T1 true ATE273712T1 (de) 2004-09-15

Family

ID=8222454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97902278T ATE273712T1 (de) 1996-02-02 1997-01-31 Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer

Country Status (9)

Country Link
US (1) US6849715B2 (de)
EP (1) EP0877622B1 (de)
AT (1) ATE273712T1 (de)
AU (1) AU1598297A (de)
DE (1) DE69730313T2 (de)
DK (1) DK0877622T3 (de)
ES (1) ES2227667T3 (de)
PT (1) PT877622E (de)
WO (1) WO1997027871A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007782B2 (en) * 2003-10-22 2011-08-30 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
WO2005039491A2 (en) * 2003-10-22 2005-05-06 The John Hopkins University Certain improved combination bacteriolytic therapy for the treatment of tumors
US12415995B2 (en) 2014-08-01 2025-09-16 Northwestern University Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
US10829752B2 (en) 2014-08-01 2020-11-10 Northwestern University Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
WO1994022476A1 (en) * 1993-03-29 1994-10-13 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants

Also Published As

Publication number Publication date
EP0877622B1 (de) 2004-08-18
US6849715B2 (en) 2005-02-01
ES2227667T3 (es) 2005-04-01
US20030103987A1 (en) 2003-06-05
DE69730313T2 (de) 2005-09-01
EP0877622A1 (de) 1998-11-18
WO1997027871A1 (en) 1997-08-07
AU1598297A (en) 1997-08-22
DE69730313D1 (de) 2004-09-23
PT877622E (pt) 2005-01-31
DK0877622T3 (da) 2004-12-20

Similar Documents

Publication Publication Date Title
Violand et al. Mechanism of the urokinase-catalyzed activation of human plasminogen.
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69421778D1 (de) Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut
DE69328550D1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
ATE319823T1 (de) Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
DE69201792D1 (de) System und kontinuierliches verfahren zur biokatalytischen entschwefelung von schwefelhaltigen heterozyklischen molekülen.
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DK0653911T3 (da) Fremgangsmåder til inaktivering af bakterier i blodpræparater med 8-methoxypsoralen
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE50014190D1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
ES8506082A1 (es) Procedimiento para la inactivacion de germenes patogenos, capaces de reproducirse
DE69831406D1 (de) Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes
NO954667D0 (no) Fremgangsmåte til deteksjon av Ki-ras mutasjoner
Adams Regeneration and the kinetics of peroxidase inactivation
DE69432055D1 (de) Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht
DE69429299D1 (de) Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen
WO1997040072A3 (en) Adam proteins and uses thereof
DE60116642D1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
ATE273712T1 (de) Methode zur inaktivierung von proteinen der ras- unterfamilie und verbindungen dafuer
ATE106250T1 (de) Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität.
DK131284A (da) Fremgangsmaade til inaktivering af stoffer, der foraarsager uforenelighedsreaktioner
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
RU94024337A (ru) Антиметастатическое средство
ATA119394A (de) Verwendung von humanem protein c zur verhinderung und behandlung von thrombozytenablagerungen
Bowen et al. Evidence that polyoma polypeptide VP1 is a serine protease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0877622

Country of ref document: EP

REN Ceased due to non-payment of the annual fee